16 completed, 5 terminated, 4 withdrawn, 3 active not recruiting. 34 Phase 2, 8 Phase 3, 3 Phase 1.
Follow IVIG: new trials by email Literature Review of IVIG trials Research Report on IVIG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis Therapeutic Plasma Exchange, Rituximab, Intravenous immunoglobulin - Idiopathic Pulmonary Fibrosis | Phase 2 | Not yet recruiting | University of Alabama at Birmingham | 52 | 2026-12-01 | 2026-10-20 |
| Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease IVIG, Aspirin, Firsekibart - Kawasaki Disease | Phase 2 / Phase 3 | Not yet recruiting | Children's Hospital of Fudan University | 90 | 2026-11-01 | 2026-10-22 |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig) Immune Globulin Intravenous - Myeloma, Non Hodgkin's Lymphoma | Phase 2 / Phase 3 | Recruiting | Monash University | 900 | 2025-04-28 | 2025-10-07 |
| Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC Poly ICLC, IVIG - Stage IV NSCLC | Phase 1 / Phase 2 | Withdrawn | VA Office of Research and Development | 2024-06-04 | 2024-09-19 | |
| Prednisone Plus IVIg vs. Prednisone for ITP During Pregnancy Prednisone, IVIg - Immune Thrombocytopenia | Phase 2 | Unknown | Peking University People's Hospital | 100 | 2023-10-19 | 2024-08-29 |
| Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial) Gamunex-C, Albumin - Immune-Mediated Necrotizing Myopathy | Phase 2 | Withdrawn | University of Washington | 2022-05-01 | 2022-10-24 | |
| IVIG Versus Plasmapheresis in the Treatment of Guillian Barrie Syndrome Patients plasmapheresis device, Intravenous immunoglobulin - Guillain-Barre Syndrome | Phase 2 / Phase 3 | Completed | Assiut University | 81 | 2021-09-01 | 2023-04-06 |
| Intravenous Immunoglobulin and Prednisolone for RPL After ART. Human Intravenous Immunoglobulins, (Privigen (R), CLS Behring), Prednisolone Tablets, Human Albumin Solution - Habitual Abortion, Recurrent Pregnancy Loss | Phase 2 | Completed | Aalborg University Hospital | 80 | 2021-01-28 | 2025-11-24 |
| Open-label Trial of IVIG in Children With PANS Privigen Injectable Product (Intravenous Immunoglobulin) - PANS Pediatric Acute-Onset Neuropsychiatric Syndrome | Phase 2 | Completed | Göteborg University | 17 | 2021-01-12 | 2026-03-06 |
| Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis Infliximab, Intravenous Immunoglobulin Therapy, Prednisone - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 2 | Terminated | ECOG-ACRIN Cancer Research Group | 1 | 2021-01-07 | 2026-09-29 |
| IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus Rituximab, IVIg - Pemphigus | Phase 2 | Active not recruiting | The University of Hong Kong | 20 | 2020-06-20 | 2025-07-08 |
| Autologous Transplant To End NMO Spectrum Disorder Rituximab, Cyclophosphamide, Mesna - Neuromyelitis Optica, Devic's Disease | Phase 2 / Phase 3 | Withdrawn | Northwestern University | 2019-11-01 | 2019-11-20 | |
| IVIG (Gamunex-C) Treatment Study for POTS Subjects IVIG, Albumin - Postural Tachycardia Syndrome | Phase 1 / Phase 2 | Completed | University of Texas Southwestern Medical Center | 30 | 2018-10-29 | 2024-09-19 |
| Cardiac Safe Transplants for Systemic Sclerosis Rituximab, Fludarabine, Cyclophosphamide - Systemic Sclerosis, Scleroderma | Phase 2 / Phase 3 | Terminated | Northwestern University | 9 | 2018-05-17 | 2020-08-12 |
| IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2 Intravenous immunoglobulin, Placebo, Rituximab - Psychosis, Autoimmune Encephalitis | Phase 2 | Active not recruiting | University of Cambridge | 70 | 2017-11-01 | 2026-05-22 |
| LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis Prednisone, Vinblastine, mercaptopurine - Langerhans Cell Histiocytosis | Phase 2 / Phase 3 | Active not recruiting | North American Consortium for Histiocytosis | 1400 | 2016-11-02 | 2026-11-10 |
| Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Pregnancy Loss IVIg - Recurrent Pregnancy Loss | Phase 2 | Completed | Tabriz University of Medical Sciences | 50 | 2016-09-20 | 2018-09-17 |
| Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Implantation Failure IVIg - Recurrent Implantation Failure | Phase 2 | Completed | Tabriz University of Medical Sciences | 50 | 2016-07-20 | 2018-09-17 |
| Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation Eculizumab, Immunoglobulin, Plasmapheresis - Antibody-mediated Rejection, Humoral Rejection | Phase 2 | Terminated | Brigham and Women's Hospital | 11 | 2013-11-01 | 2017-09-21 |
| Antibiotic Treatment and Intravenous Immunoglobulin Trial for PANDAS Sertraline+Antibiotic (penicillin/azithromycin), Sertraline+placebo, IVIG - Pandas | Phase 2 | Withdrawn | CNS Onlus | 2013-06-01 | 2023-02-21 |
Showing 20 of 34. Sign in to see all of them.
Autoimmune Diseases of the Nervous System (2) · Kidney Failure, Chronic (2) · Neoplasms (2) · Pemphigus (2) · Purpura, Thrombocytopenic, Idiopathic (2) · Abortion, Habitual (1) · Abortion, Spontaneous (1) · Agammaglobulinemia (1) · Alzheimer Disease (1) · Autoimmune Diseases (1) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Neoplasms (1) · Disease Progression (1) · Drug Resistant Epilepsy (1) · Epilepsies, Partial (1)
Grifols Therapeutics LLC (4) · Northwestern University (2) · Tabriz University of Medical Sciences (2) · Aalborg University Hospital (1) · Assiut University (1) · Brigham and Women's Hospital (1) · CNS Onlus (1) · Cedars-Sinai Medical Center (1) · Children's Hospital of Fudan University (1) · Columbia University (1) · ECOG-ACRIN Cancer Research Group (1) · Emory University (1) · GammaCan (1) · Göteborg University (1) · Haukeland University Hospital (1)
United States (19) · Canada (2) · China (2) · Germany (2) · Iran (2) · Israel (2) · Sweden (2) · United Kingdom (2) · Australia (1) · Austria (1) · Czechia (1) · Denmark (1) · Egypt (1) · Greece (1) · Hong Kong (1)
Mehdi Yousefi, Immunologist (2) · Mohammad Nouri, Ph.D (2) · Richard Burt, MD (2) · Alasdair Coles, PhD FRCP (1) · Anil K Chandraker, MD (1) · Avroy A. Fanaroff, MD (1) · Carlos Rodriguez-Galindo, MD (1) · Charles M. Epstein, M.D. (1) · Charles R. Bauer, MD (1) · Christopher Gillberg, Professor (1) · Curie Ahn, MD (1) · Dan Aderka, M.D. (1) · Elisabeth Farbu, MD, PhD (1) · Elizabeth C. Wright, PhD (1) · Fang Liu, MD (1)
PMID 12765346, PMID 17166218, PMID 19710204, PMID 19819893, PMID 21095154, PMID 22889462, PMID 24628478, PMID 18645164, PMID 23375965, PMID 25090414, PMID 26083430, PMID 26844479, PMID 31174586, PMID 32612255, PMID 33568350, PMID 35933358, PMID 36137638, PMID 38509495, PMID 41263919, PMID 8133853, PMID 9686724
U01HD019897 (1), U10HD021364 (1), U10HD021373 (1), U10HD021385 (1), U10HD021397 (1), U10HD021415 (1), UG1CA189828 (1)